Recombinant Vaccine Against Helminths in Pichia pastoris
Summary
USPTO published patent application US20260092089A1 by Fundação Oswaldo Cruz disclosing recombinant production of Sm14 Schistosoma mansoni vaccine antigen using genetically engineered Pichia pastoris strains with methanol-inducible (AOX1) and constitutive (GAP) promoters. The application covers synthetic gene construction, fermentation processes, and protein purification methods scalable for industrial vaccine manufacturing.
What changed
The USPTO published a patent application (US20260092089A1) by Fundação Oswaldo Cruz for a recombinant vaccine against helminths using Pichia pastoris yeast as expression host. The invention describes creation of a synthetic gene optimized for high expression of Sm14 Schistosoma mansoni protein, cloned under two promoter systems (AOX1 methanol-inducible and GAP constitutive) for efficient production of the vaccine antigen. The application covers the genetic constructs, fermentation methods, and purification processes for industrial-scale manufacturing.
This is a patent application publication only—no compliance obligations or deadlines apply. Parties interested in this technology should monitor application status for examination results. Researchers and vaccine developers may explore potential licensing or partnership opportunities with Fundação Oswaldo Cruz if the patent proceeds to grant. Commercial development would require separate regulatory approvals for any resulting vaccine product.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RECOMBINANT VACCINE AGAINST HELMINTHS IN PICHIA PASTORIS AND METHODS FOR PRODUCING AND PURIFYING PROTEINS FOR USE AS VACCINES AGAINST HELMINTHS
Application US20260092089A1 Kind: A1 Apr 02, 2026
Assignee
Fundação Oswaldo Cruz
Inventors
Miriam TENDLER, Andrew J. SIMPSON, Celso Raul Romero RAMOS
Abstract
The present invention is related to the recombinant production of proteins by using a synthetic gene for high protein expression in Pichia pastoris. More specifically, the invention describes the production of Sm14 Schistosoma mansoni recombinant protein, where a synthetic gene was created to promote high expression of such protein, a gene which was cloned under control of two types of Pichia pastoris promoters: methanol-inducible promoter (AOXI) and constituent promoter (GAP). With these constructions, Pichia pastoris strains were genetically manipulated to efficiently produce vaccine antigen Sm14. The processes to produce and purify this protein from P. pastoris cells, which can be escalated for their industrial production, were also improved.
CPC Classifications
C07K 14/43559 A61K 39/0003 C12N 15/815
Filing Date
2025-11-28
Application No.
19403587
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Peptides (C07K) publishes new changes.